Last updated on June 2017

First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas


Brief description of study

The ATR(ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas. The purpose of the proposed trial is to evaluate the safety and tolerability of BAY1895344, and to identify the maximum tolerated dose of BAY1895344 that could be safely given to cancer patients. Further, the response of the cancer to the treatment will be determined.

Clinical Study Identifier: NCT03188965

Contact Investigators or Research Sites near you

Start Over

Bayer Clinical Trials Contact

University of Texas MD Anderson Cancer Center
Houston, TX United States
  Connect »

Bayer Clinical Trials Contact

National University Hospital
Singapore, Singapore
  Connect »

Bayer Clinical Trials Contact

Royal Marsden NHS Trust (Surrey)
Sutton, United Kingdom
  Connect »

Bayer Clinical Trials Contact

Freeman Hospital
Newcastle Upon Tyne, United Kingdom
  Connect »